This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)

This study has been completed.
Information provided by:
Chugai Pharmaceutical Identifier:
First received: September 2, 2005
Last updated: December 21, 2009
Last verified: December 2009
This is an open-label, extension, Phase III study to evaluate the long-term safety, efficacy and PK of MRA in patients with pJIA who participated in Study MRA318JP.

Condition Intervention Phase
Polyarticular Juvenile Idiopathic Arthritis Drug: MRA(Tocilizumab) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP

Resource links provided by NLM:

Further study details as provided by Chugai Pharmaceutical:

Primary Outcome Measures:
  • Efficacy:Percentage of patients showing 30% improvement in the JIA core set every 3M, LOBS [ Time Frame: every 3 months ]
  • Safety:Incidence and severity of adverse events and adverse drug reactions [ Time Frame: whole period ]
  • Pharmacokinetics:The time course of the trough values for the serum MRA concentration [ Time Frame: whole period ]

Secondary Outcome Measures:
  • Efficacy:The time course of the percentage of patients showing 30%, 50%, and 70% improvement in the JIA core set, each variable of the JIA core set, CRP, pain every 3M, LOBS [ Time Frame: every 3 months ]

Enrollment: 19
Study Start Date: February 2005
Study Completion Date: June 2009
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: MRA(Tocilizumab)


Ages Eligible for Study:   2 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Of the patients who received three infusions with MRA in the previous study and for whom a last observation was conducted
  • the patients who did not have problems with safety in the previous study"

Exclusion criteria

  • Patients who were not enrolled by 3 months after completion of the previous study
  • Patients who received any of the following since completion of the previous study until initiation of treatment in the present study

    1. DMARDs or immunosuppressants
    2. Intravenous and intramuscular injection of corticosteroids
    3. Plasma exchange therapy
    4. Other drugs and therapies that may affect evaluation of drug efficacy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00144625

Sponsors and Collaborators
Chugai Pharmaceutical
Study Director: Takahiro Kakehi Chugai Pharmaceutical
  More Information

Responsible Party: Chugai Pharmaceutical Identifier: NCT00144625     History of Changes
Other Study ID Numbers: MRA319JP
Study First Received: September 2, 2005
Last Updated: December 21, 2009

Additional relevant MeSH terms:
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on June 23, 2017